164 related articles for article (PubMed ID: 19585686)
1. Lenalidomide for the treatment of relapsed multiple myeloma.
Gajraj E; Chung H; Boysen M; Barnett DB; Longson C
Lancet Oncol; 2009 Jul; 10(7):647-8. PubMed ID: 19585686
[No Abstract] [Full Text] [Related]
2. Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.
Gooding S; Lau IJ; Sheikh M; Roberts P; Wong J; Dickens E; Bullement A; Elvidge J; Lee D; Ramasamy K
PLoS One; 2015; 10(9):e0136207. PubMed ID: 26367874
[TBL] [Abstract][Full Text] [Related]
3. Spotlight on lenalidomide in relapsed or refractory multiple myeloma.
Scott LJ; Lyseng-Williamson KA
BioDrugs; 2011 Oct; 25(5):333-7. PubMed ID: 21942918
[TBL] [Abstract][Full Text] [Related]
4. The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Bonkowski J; Vermeulen LC; Kolesar JM
J Oncol Pharm Pract; 2010 Dec; 16(4):223-32. PubMed ID: 19910392
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of lenalidomide in multiple myeloma.
Schey S; Higginson I
Expert Rev Pharmacoecon Outcomes Res; 2010 Jun; 10(3):229-38. PubMed ID: 20545587
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
Jakubowiak AJ; Campioni M; Benedict Á; Houisse I; Tichy E; Giannopoulou A; Aggarwal SK; Barber BL; Panjabi S
J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. European Journal of Haematology 2010; 85 (6):484-491.
Ishak J; Rodrigues F
Eur J Haematol; 2011 Jul; 87(1):95; author reply 96-7. PubMed ID: 21692852
[No Abstract] [Full Text] [Related]
8. Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis.
Gong CL; Studdert AL; Liedtke M
Am J Hematol; 2019 Mar; 94(3):E68-E70. PubMed ID: 30536952
[No Abstract] [Full Text] [Related]
9. [The use of lenalidomide in the treatment of multiple myeloma].
Holánek M; Hájek R
Klin Onkol; 2010; 23(2):67-72. PubMed ID: 20465083
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide and its analogues: comparative clinical efficacy and safety, and cost-effectiveness.
Paumgartten FJ
Cad Saude Publica; 2014 Apr; 30(4):684-6. PubMed ID: 24896044
[No Abstract] [Full Text] [Related]
12. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
Mariz JM; Esteves GV
Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
Möller J; Nicklasson L; Murthy A
J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide in multiple myeloma.
Thomas SK; Richards TA; Weber DM
Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
16. Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.
Morita Y; Shimada T; Yamaguchi T; Rai S; Hirase C; Emoto M; Serizawa K; Taniguchi Y; Ojima M; Tatsumi Y; Ashida T; Matsumura I
Int J Hematol; 2011 Dec; 94(6):583-4. PubMed ID: 22127558
[No Abstract] [Full Text] [Related]
17. Lenalidomide: new drug. Myeloma: many questions remain unanswered.
Prescrire Int; 2008 Dec; 17(98):230-2. PubMed ID: 19422142
[TBL] [Abstract][Full Text] [Related]
18. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Armoiry X; Fagnani F; Benboubker L; Facon T; Fermand JP; Hulin C; Moreau P; Aulagner G
J Clin Pharm Ther; 2011 Feb; 36(1):19-26. PubMed ID: 21198717
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales.
Brown RE; Stern S; Dhanasiri S; Schey S
Eur J Health Econ; 2013 Jun; 14(3):507-14. PubMed ID: 22572968
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide in the treatment of multiple myeloma.
Rao KV
Am J Health Syst Pharm; 2007 Sep; 64(17):1799-807. PubMed ID: 17724360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]